Literature DB >> 19763674

Sustained weight loss and improvement of quality of life after laparoscopic adjustable gastric banding for morbid obesity: a single surgeon experience in Ireland.

K H Chang1, E T Condon, E J O'Connor, O J McAnena.   

Abstract

BACKGROUND: Although substantial weight loss is the primary outcome following bariatric surgery, changes in obesity-related morbidity and quality of life (QoL) are equally important. This study reports on weight loss, QoL and health outcomes following laparoscopic adjustable gastric banding (LAGB).
METHODS: Bariatric analysis and reporting outcome system questionnaire survey was carried out on patients who had LAGB. Patients' body weight, body mass index, QoL and co-morbidities were recorded.
RESULTS: Twenty-three of 26 patients answered the questionnaire (response rate of 92%). Fifteen patients (60%) achieved over 50% excess weight loss. Twenty-two patients (84.6%) reported improvement in QoL. Co-morbidities in 18 patients (75%) resolved or improved. One patient had postoperative aspiration pneumonia and no other morbidity was recorded.
CONCLUSIONS: Laparoscopic adjustable gastric banding is a safe and feasible method of bariatric surgery. It can achieve satisfactory weight loss with significant improvement in QoL and co-morbidity provided patients undergo thorough preoperative preparation and rigorous postoperative follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19763674     DOI: 10.1007/s11845-009-0423-4

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  8 in total

1.  Overweight and obesity worldwide now estimated to involve 1.7 billion people.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2003-06       Impact factor: 4.129

2.  Bariatric analysis and reporting outcome system (BAROS)

Authors:  H E Oria; M K Moorehead
Journal:  Obes Surg       Date:  1998-10       Impact factor: 4.129

3.  Laparoscopic Adjustable Silicone Gastric Banding: Technique and Results.

Authors: 
Journal:  Obes Surg       Date:  1995-11       Impact factor: 4.129

Review 4.  Methods for Voluntary Weight Loss and Control. Proceedings of NIH Technology Assessment Conference. Bethesda, Maryland, 30 March-1 April 1992.

Authors: 
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

5.  Laparoscopic adjustable gastric banding.

Authors:  M Belachew; M Legrand; V Vincent; M Lismonde; N Le Docte; V Deschamps
Journal:  World J Surg       Date:  1998-09       Impact factor: 3.352

6.  Complications after laparoscopic adjustable gastric banding for morbid obesity: experience with 1,000 patients over 7 years.

Authors:  Jean-Marc Chevallier; Franck Zinzindohoué; Richard Douard; Jean-Philippe Blanche; Jean-Louis Berta; Jean-Jacques Altman; Paul-Henri Cugnenc
Journal:  Obes Surg       Date:  2004-03       Impact factor: 4.129

7.  Swedish obese subjects (SOS)--an intervention study of obesity. Baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined.

Authors:  M Sullivan; J Karlsson; L Sjöström; L Backman; C Bengtsson; C Bouchard; S Dahlgren; E Jonsson; B Larsson; S Lindstedt
Journal:  Int J Obes Relat Metab Disord       Date:  1993-09

8.  Esophageal dilation after laparoscopic adjustable gastric banding.

Authors:  L Milone; A Daud; E Durak; L Olivero-Rivera; B Schrope; W B Inabnet; D Davis; M Bessler
Journal:  Surg Endosc       Date:  2007-11-20       Impact factor: 4.584

  8 in total
  2 in total

Review 1.  Analysis of health-related quality-of-life instruments measuring the impact of bariatric surgery: systematic review of the instruments used and their content validity.

Authors:  Raed Tayyem; Abdulmajid Ali; John Atkinson; Colin R Martin
Journal:  Patient       Date:  2011       Impact factor: 3.883

2.  The role of laparoscopic sleeve gastrectomy as a treatment for morbid obesity; review of outcomes.

Authors:  B M Moloney; D A Hynes; M E Kelly; A Iqbal; E O'Connor; D Lowe; O J McAnena
Journal:  Ir J Med Sci       Date:  2016-07-28       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.